Granules India Ltd
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.[1]
- Market Cap ₹ 10,261 Cr.
- Current Price ₹ 423
- High / Low ₹ 480 / 272
- Stock P/E 26.0
- Book Value ₹ 122
- Dividend Yield 0.35 %
- ROCE 19.4 %
- ROE 19.1 %
- Face Value ₹ 1.00
Pros
- Company's median sales growth is 19.2% of last 10 years
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
654 | 761 | 1,084 | 1,292 | 1,357 | 1,411 | 1,685 | 2,279 | 2,599 | 3,238 | 3,765 | 4,512 | 4,526 | |
575 | 676 | 925 | 1,082 | 1,081 | 1,112 | 1,406 | 1,895 | 2,073 | 2,382 | 3,038 | 3,597 | 3,698 | |
Operating Profit | 79 | 86 | 159 | 210 | 276 | 299 | 278 | 384 | 526 | 856 | 727 | 915 | 828 |
OPM % | 12% | 11% | 15% | 16% | 20% | 21% | 17% | 17% | 20% | 26% | 19% | 20% | 18% |
1 | 1 | 4 | 3 | 5 | 35 | 27 | 75 | 90 | 26 | 13 | 12 | 6 | |
Interest | 17 | 18 | 20 | 32 | 37 | 32 | 33 | 28 | 27 | 26 | 23 | 56 | 96 |
Depreciation | 21 | 23 | 30 | 53 | 58 | 72 | 76 | 105 | 137 | 151 | 159 | 184 | 203 |
Profit before tax | 43 | 46 | 112 | 128 | 186 | 230 | 196 | 326 | 451 | 704 | 558 | 687 | 536 |
Tax % | 30% | 30% | 33% | 29% | 33% | 28% | 32% | 27% | 26% | 22% | 26% | 25% | |
30 | 33 | 75 | 91 | 123 | 165 | 133 | 236 | 335 | 549 | 413 | 517 | 395 | |
EPS in Rs | 1.49 | 1.62 | 3.71 | 4.45 | 5.68 | 7.19 | 5.22 | 9.30 | 13.19 | 22.18 | 16.64 | 21.34 | 16.31 |
Dividend Payout % | 13% | 12% | 9% | 11% | 11% | 13% | 19% | 11% | 8% | 7% | 9% | 7% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | 22% |
3 Years: | 20% |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | 32% |
5 Years: | 31% |
3 Years: | 18% |
TTM: | -22% |
Stock Price CAGR | |
---|---|
10 Years: | 27% |
5 Years: | 31% |
3 Years: | 6% |
1 Year: | 43% |
Return on Equity | |
---|---|
10 Years: | 20% |
5 Years: | 20% |
3 Years: | 21% |
Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 20 | 20 | 20 | 20 | 22 | 23 | 25 | 25 | 25 | 25 | 25 | 24 | 24 |
Reserves | 225 | 255 | 336 | 411 | 640 | 881 | 1,279 | 1,504 | 1,818 | 2,149 | 2,562 | 2,811 | 2,943 |
204 | 270 | 442 | 482 | 641 | 656 | 978 | 991 | 892 | 849 | 1,106 | 1,136 | 1,380 | |
123 | 137 | 194 | 289 | 260 | 319 | 388 | 458 | 487 | 690 | 819 | 932 | 918 | |
Total Liabilities | 571 | 683 | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,903 | 5,265 |
250 | 263 | 482 | 617 | 560 | 644 | 777 | 944 | 1,204 | 1,332 | 1,541 | 1,911 | 2,063 | |
CWIP | 29 | 109 | 125 | 62 | 77 | 267 | 515 | 496 | 294 | 239 | 356 | 239 | 219 |
Investments | 0 | 10 | 0 | 0 | 70 | 108 | 157 | 210 | 19 | 19 | 20 | 21 | 21 |
291 | 301 | 385 | 524 | 856 | 859 | 1,222 | 1,328 | 1,706 | 2,123 | 2,594 | 2,732 | 2,961 | |
Total Assets | 571 | 683 | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,903 | 5,265 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
26 | 91 | 108 | 150 | 151 | 188 | -1 | 262 | 476 | 432 | 332 | 739 | |
-54 | -128 | -255 | -146 | -162 | -326 | -462 | -270 | -160 | -277 | -379 | -192 | |
49 | 46 | 147 | 19 | 86 | 56 | 529 | -17 | -213 | -299 | 190 | -440 | |
Net Cash Flow | 20 | 10 | 0 | 24 | 75 | -82 | 66 | -25 | 103 | -144 | 143 | 107 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 53 | 34 | 37 | 39 | 101 | 108 | 136 | 108 | 93 | 86 | 90 | 77 |
Inventory Days | 97 | 107 | 99 | 110 | 128 | 145 | 114 | 112 | 125 | 205 | 190 | 182 |
Days Payable | 67 | 72 | 77 | 92 | 91 | 116 | 112 | 94 | 102 | 142 | 124 | 124 |
Cash Conversion Cycle | 83 | 69 | 59 | 57 | 138 | 137 | 138 | 126 | 116 | 150 | 156 | 135 |
Working Capital Days | 65 | 56 | 48 | 41 | 115 | 120 | 156 | 120 | 116 | 109 | 119 | 102 |
ROCE % | 15% | 13% | 20% | 19% | 20% | 18% | 12% | 15% | 17% | 25% | 17% | 19% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Of Schedule of the Earnings Conference call for Q4 and financial year ended on March 31, 2024.
- Update 1 May
- Board Meeting Intimation for Consideration And Approval For The Audited Financial Results For The Fourth Quarter And Financial Year Ended On March 31, 2024 And Final Dividend For FY24, If Any. 30 Apr
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
30 Apr - Receipt of ANDA approval for Colchicine Capsules
- Compliances-Reg.24(A)-Annual Secretarial Compliance 18 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Jan 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT REC
-
Jan 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Jul 2021Transcript PPT
-
Jun 2021TranscriptPPT
-
May 2021TranscriptPPT
-
May 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Oct 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jan 2020Transcript PPT
-
Dec 2019TranscriptNotesPPT
-
Oct 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Jul 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
Apr 2016TranscriptNotesPPT
-
Jan 2016TranscriptNotesPPT
Business Segments FY23